The browser you are currently using is not being supported by this website, please upgrade to a more recent browser for a better viewing experience.
Independent Adviser(s): Simmons Corporate Finance (Rule 18)
Company Meeting Date: 06/12/2016
Offer Type: Partial
Neuren Pharmaceuticals Limited (“Neuren”) proposed to raise additional capital by allotting up to 100 million new ordinary voting securities to Walker Group Holdings Pty Limited (“Walker”) in several tranches in the period up to and including 20 June 2017 (the “Proposed Allotments”). The issue price for the voting securities to be allotted will be set on the volume weighted average price at which Neuren’s ordinary voting securities are traded on the Australian Securities Exchange in the 10 trading days prior to each allotment. The Panel granted an exemption from rule 16(d) and rule 7(d) to facilitate this.
Prior to the Proposed Allotments, Walker along with its associates held or controlled 18.39% of the voting securities on issue in Neuren. After the Proposed Allotments, the percentage of voting securities to be held and controlled by Walker along with its associates will be up to 24.04%.
Neuren sought shareholder approval for the Proposed Allotments in accordance with rule 7(d). At a special meeting on 6 December 2016, Neuren shareholders approved the Proposed Allotments.